1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Global Peptide Therapeutics Market & Clinical Trials Insight 2022

Global Peptide Therapeutics Market & Clinical Trials Insight 2022

  • May 2017
  • 1300 pages
  • ID: 4919724
  • Format: PDF

Summary

Table of Contents

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report highlights:
• Fundamentals of Peptide Therapeutics
• Peptide Therapeutics by Applications & Indications
• Peptides Clinical Trials Insight by Phase, Indication & Company
• Insight on 688 Peptide Drugs in Clinical Trials
• Clinical & Patent Insight on 119 Marketed Peptides
• Future Peptide Therapeutics Market Outlook

“Global Peptide Therapeutics Market & Clinical Trials Insight 2022” report gives comprehensive insight into the various clinical and non-clinical issues involved in the development of global peptide drug market. In recent years, peptides have emerged as one of the important classes of therapeutic molecules which have been developed by varied pharmaceutical and biotech companies in order to attain a targeted drug discovery for several ailments. As per report findings, there are 688 peptide drugs in clinical pipeline and more than 100 peptide based drugs commercially available in the market.

Research and development of peptide based therapeutics has gained significant momentum in past several decades due to high safety and efficacy profiles. This drives the pharmaceutical companies to invest more in this segment to come forth with competitive products for marketing.

Owing to large number of diseases indications they have potential to occupy large market shares and generate significant amount of revenues. Pharmaceutical companies focused their efforts to tap this market segment by investing more funds in research and development activities.

As a result, newer peptide based therapeutics are entering in global market and others are at various phases of clinical trials which are expected to get marketing approval in near future. Increased competition with drugs belonging to other categories for same disease indication is also expected to increase with time in this segment.

Peptides are used in drug development programs to provide superior pharmacological effects and alleviate patient medical condition. They have high safety and efficacy due to which they are widely accepted among physicians and patients for treatment of various ailments. In clinical practice, they are used for diabetes, various kinds of cancers, infectious diseases, cardiovascular and many other diseases indications. They could be easily modified as compared to other drug categories making them highly profitable for sponsors.

Due to versatility they could be used for several medical indications leading to higher market penetration. Besides therapeutics effects, mature market give advantages related to familiarity and relatively easy marketing approval.

Peptide drugs are versatile in nature due to which they can be used for treating various life threatening diseases. Modifications to achieve superior pharmacological effect are relatively easy due to which they can be introduced in market for different diseases categories. Pharmaceutical companies can generate significant revenues in global market due to this property.

Diabetes, Central Nervous System (CNS), hormonal systems, cardiovascular diseases, oncology and other diseases have effective peptide based therapeutics. Potential of generating significant revenues by these drugs by pharmaceutical companies is expected to cause increase funding in research and development segment. Market size of these drugs is expected to increase several folds in near future as more innovative drugs for multiple diseases indications would be introduced in market in coming years.

Rapidly increasing number of clinical trials reflects the unmet demand for better for peptide therapeutics for patients. Due to escalating disease incidences, it has become imperative to take necessary steps to introduce innovative peptide based therapeutics rapidly in global market.

Some therapeutics like GLP-1 is expected substitute for insulin which has one of the largest market size and widespread acceptability among patients and physicians. But pharmacological efficacy of this innovative drug is clinically equivalent to insulin with additional benefit of regulation which is not found in its counterpart. Market success rates of new peptide based therapeutics will depend on the significance of data generated during clinical trials and effectiveness of marketing strategy.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Felipe helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Periodontitis - Pipeline Review, H1 2019

Periodontitis - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Periodontitis - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Periodontitis - Pipeline Review, H1 2019, provides an overview of the ...

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2019

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2019

  • $ 3500
  • March 2019

72 kDa Type IV Collagenase (Matrix Metalloproteinase 2 or Gelatinase A or Neutrophil Gelatinase or 72 kDa Gelatinase or TBE 1 or MMP2 or EC 3.4.24.24) - Pipeline Review, H1 2019Summary72 kDa Type IV Collagenase ...

Crigler-Najjar Syndrome - Pipeline Review, H1 2019

Crigler-Najjar Syndrome - Pipeline Review, H1 2019

  • $ 2000
  • March 2019

Crigler-Najjar Syndrome - Pipeline Review, H1 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Crigler-Najjar Syndrome - Pipeline Review, H1 2019, provides ...


ref:plp2017

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on